<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Complement Altern Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Complement Altern Med</journal-id><journal-title-group><journal-title>BMC Complementary and Alternative Medicine</journal-title></journal-title-group><issn pub-type="epub">1472-6882</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27776494</article-id><article-id pub-id-type="pmc">5075981</article-id><article-id pub-id-type="publisher-id">1386</article-id><article-id pub-id-type="doi">10.1186/s12906-016-1386-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Moxibustion treatment for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Bao</surname><given-names>Chunhui</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Jingzhi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Liu</surname><given-names>Jinmei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Huirong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Luyi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Yin</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Zhihai</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Yongzheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Siyao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Xiaoqing</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wu</surname><given-names>Huangan</given-names></name><address><phone>86-21-64644238</phone><email>wuhuangan@126.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Key Laboratory of Acupuncture and Immunological Effects, Shanghai University of Traditional Chinese Medicine, 650 South Wanping Road, Shanghai, 200030 China </aff><aff id="Aff2"><label>2</label>Outpatient Department, Shanghai Research Institute of Acupuncture and Meridian, Shanghai University of Traditional Chinese Medicine, Shanghai, 200030 China </aff><aff id="Aff3"><label>3</label>Department of Acupuncture-Moxibustion, Yueyang Integrated Chinese and Western Medicine Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437 China </aff><aff id="Aff4"><label>4</label>Department of Acupuncture-Moxibustion, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200082 China </aff><aff id="Aff5"><label>5</label>Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, 200032 China </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>16</volume><elocation-id>408</elocation-id><history><date date-type="received"><day>17</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>18</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Irritable bowel syndrome (IBS) is a worldwide disease with high morbidity. The effect of current treatment with Western medicine is not satisfactory. Although moxibustion treatment is widely used for gastrointestinal diseases, randomized controlled trials on the use of this treatment for IBS are limited. This study aims to evaluate the clinical efficacy and safety of moxibustion treatment in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).</p></sec><sec><title>Methods/design</title><p>A multi-center, randomized, single-blind and placebo-controlled trial is employed. 104 cases will be divided into two groups: (1) a mild-warm moxibustion group in which moxa stick is 3&#x02013;5&#x000a0;cm away from acupuncture points and the skin temperature is maintained at 43&#x02009;&#x000b1;&#x02009;1&#x000a0;&#x000b0;C; and (2) a placebo moxibustion group in which moxa stick is 8&#x02013;10&#x000a0;cm away from acupuncture points and the skin temperature is maintained at 37&#x02009;&#x000b1;&#x02009;1&#x000a0;&#x000b0;C. Moxibustion is performed on bilateral ST25 and ST36 in the two groups for 30&#x000a0;min each time, three times a week for 6&#x000a0;weeks. The patients are followed up at the 12th and 18th weeks. Adequate relief is used as a primary outcome measure; IBS symptom severity score, Bristol stool form scale, IBS quality-of-life questionnaire, and hospital anxiety and depression scale are used as secondary outcome measures.</p></sec><sec><title>Discussion</title><p>This study aims to demonstrate the safety and efficacy of moxibustion treatment for IBS-D, which may validate moxibustion as an effective therapy for treating IBS-D.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov identifier <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">NCT02421627</ext-link> (8 April 2015).</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Diarrhea</kwd><kwd>Irritable bowel syndrome</kwd><kwd>Moxibustion</kwd><kwd>Randomized controlled trial</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Key Basic Research Program of China (973 program)</institution></funding-source><award-id>2015CB554501</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Huangan</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81503656</award-id><principal-award-recipient><name><surname>Bao</surname><given-names>Chunhui</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Shanghai Sailing Program</institution></funding-source><award-id>15YF1411200</award-id><principal-award-recipient><name><surname>Bao</surname><given-names>Chunhui</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007279</institution-id><institution>Shanghai Municipal Health Bureau</institution></institution-wrap></funding-source><award-id>20154Y0138</award-id><principal-award-recipient><name><surname>Bao</surname><given-names>Chunhui</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent abdominal pain or discomfort in combination with disturbed bowel habits in the absence of an identifiable cause [<xref ref-type="bibr" rid="CR1">1</xref>]. Currently, the morbidity of IBS is 7&#x02013;21&#x000a0;% worldwide, it can occur at any age, mainly between 30 and 50&#x000a0;years [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Of all types, diarrhea-predominant irritable bowel syndrome (IBS-D) is the most common subtype [<xref ref-type="bibr" rid="CR4">4</xref>]. IBS has gained attention because it significantly reduces people&#x02019;s quality of life (QOL) and influences medical resources and social economy [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p>The pathogenesis of IBS is unclear. It is probably related to visceral hypersensitivity, brain&#x02013;gut regulation dysfunction, intestinal infection and inflammation, and psychological factors [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. The current treatment for IBS is to remove the inducing factors and relieve the symptoms. However, the poor efficacy and the side effects from long-term drug use have forced patients to seek alternative interventions [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. In recent years, physicians as well as patients are more interested in complementary and alternative medicine including acupuncture and moxibustion [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. While much less popular than acupuncture, moxibustion exerts its effects through warm stimulation caused by burning moxa on the acupuncture points. Mild-warm moxibustion is a therapy in which a burning moxa stick is pointed to a moxibustion site (usually an acupuncture point) at a distance to make the patient have a warm sensation but without any burning pain. Because of its low cost and easy application, moxibustion is often used to treat gastrointestinal diseases. However, its efficacy on IBS has not been confirmed. Previous trials on the treatment of IBS with moxibustion were often lack of strict control of randomization and related risk of bias, which makes the conclusions less convincing [<xref ref-type="bibr" rid="CR12">12</xref>]. A recent randomized controlled trial on herb-partitioned moxibustion for IBS also failed to fully confirm its effectiveness, and the results still need to be verified [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Therefore, a multi-center, parallel-group, 1:1 allocation, randomized, single-blind and placebo-controlled trial has been designed in this study. The aim is to evaluate the clinical efficacy and safety of moxibustion in patients with IBS-D. The results may provide evidence for the clinical use of moxibustion in patients with IBS-D.</p></sec><sec id="Sec2"><title>Methods/design</title><sec id="Sec3"><title>Study design</title><p>This study is a multi-center, randomized, single-blind and placebo-controlled clinical trial. All the subjects will be enrolled according to the ROME III IBS-D diagnostic criteria [<xref ref-type="bibr" rid="CR14">14</xref>]. The flowchart of the trial is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow diagram of study design</p></caption><graphic xlink:href="12906_2016_1386_Fig1_HTML" id="MO1"/></fig>
</p></sec><sec id="Sec4"><title>Patients</title><p>All the 104 cases will be recruited from the following three research centers: the Bowel Disease Clinic of the Shanghai Research Institute of Acupuncture and Meridian; the Department of Acupuncture-Moxibustion of the Yueyang Integrated Chinese and Western Medicine Hospital at the Shanghai University of Traditional Chinese Medicine (TCM); and the Department of Acupuncture-Moxibustion of the Shanghai TCM-Integrated Hospital, Shanghai University of TCM. Recruitment notices were released on TV, newspapers, and magazines. Also, recruiting posters were posted in the community and public places nearby to ensure enough subjects.</p></sec><sec id="Sec5"><title>Sample size calculation</title><p>Previous studies showed that the effective rates of the mild-warm moxibustion group and the placebo group were 88.7&#x000a0;% [<xref ref-type="bibr" rid="CR15">15</xref>] and 62&#x000a0;% [<xref ref-type="bibr" rid="CR16">16</xref>], respectively. Based on these values, the sample size in this study is estimated as follows:<disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ n = {\left(Ua+Ub\right)}^2\left(1 + 1/k\right)P\left(1-P\right)/{\left(Pe-Pc\right)}^2 $$\end{document}</tex-math><mml:math id="M2"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mspace width="0.25em"/><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mi>U</mml:mi><mml:mi>a</mml:mi><mml:mo>+</mml:mo><mml:mi>U</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mspace width="0.25em"/><mml:mo>+</mml:mo><mml:mspace width="0.25em"/><mml:mn>1</mml:mn><mml:mo stretchy="true">/</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:mfenced><mml:mi>P</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>P</mml:mi></mml:mrow></mml:mfenced><mml:mo stretchy="true">/</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mrow><mml:mi>P</mml:mi><mml:mi>e</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>P</mml:mi><mml:mi>c</mml:mi></mml:mrow></mml:mfenced><mml:mn>2</mml:mn></mml:msup></mml:math><graphic xlink:href="12906_2016_1386_Article_Equa.gif" position="anchor"/></alternatives></disp-formula>
</p><p>The significant level is 0.05; the power of test is 1&#x02009;&#x02212;&#x02009;<italic>&#x003b2;</italic>&#x02009;=&#x02009;0.9, <italic>k</italic>&#x02009;=&#x02009;1; and the sample loss rate is 15&#x000a0;%. The required sample size is 52 by calculation, and no less than 104 cases should be included in the two groups.</p></sec><sec id="Sec6"><title>Randomization</title><p>In this study, random numbers are generated by SPSS and kept by a clinical research coordinator who has no contact with the patients. The allocation will be concealed in sequentially numbered, opaque, sealed envelopes containing the randomization assignments. An eligible subject who meets the inclusion criteria will sign the informed consent. Researchers in a research center will use a random number and grouping information sent by telephone, text message, or e-mail from the clinical research coordinator, and assign the subject into moxibustion or placebo moxibustion groups.</p></sec><sec id="Sec7"><title>Blinding</title><p>The practitioners could not be blinded due to the unique nature of moxibustion treatments. The patients are blinded to the treatment. They are kept in individual isolated rooms, avoiding communication among them. Furthermore, Researchers responsible for data collection, analysis, and statistics have no information about grouping and treatment.</p></sec><sec id="Sec8"><title>Eligibility</title><p>Inclusion criteria:<list list-type="bullet"><list-item><p>Patients who are enrolled according to the ROME III IBS-D diagnostic criteria</p></list-item><list-item><p>Patients aged between 18 and 65&#x000a0;years</p></list-item><list-item><p>Patients who have signed informed consent</p></list-item></list>
</p><p>Exclusion criteria:<list list-type="bullet"><list-item><p>Patients who present with intestinal organic disorders</p></list-item><list-item><p>Patients who have been administered drugs for treating IBS-D or other drugs that may influence the trial</p></list-item><list-item><p>Patients who have a severe disease of the heart, brain, lung, liver, kidney, or hematopoietic system</p></list-item><list-item><p>Patients who are diagnosed with a psychiatric disorder</p></list-item><list-item><p>Women in pregnancy or nursing</p></list-item><list-item><p>Patients who have a history of abdominal surgery</p></list-item><list-item><p>Patients who have been treated by acupuncture and moxibustion</p></list-item></list>
</p></sec><sec id="Sec9"><title>Interventions</title><sec id="Sec10"><title>Treatment group</title><p>For mild-warm moxibustion treatment, bilateral ST25 and ST36 points are used (reference for PRC National Standard GB/T 12346&#x02013;2006) [<xref ref-type="bibr" rid="CR17">17</xref>]. A moxa stick (diameter 3&#x000a0;cm) is ignited and positioned with a supporting device so that the tip of the moxa stick is 3&#x02013;5&#x000a0;cm above the acupuncture point. The temperature of the acupuncture point is monitored with an infrared thermometer (Fluke 62, USA) and maintained at 43&#x02009;&#x000b1;&#x02009;1&#x000a0;&#x000b0;C to make the subject feel warm without any burning pain. The treatment lasts for 30&#x000a0;min each time, three times a week for 6&#x000a0;weeks (18 times). After the treatment, follow-ups are made at weeks 12 and 18.</p></sec><sec id="Sec11"><title>Control group</title><p>For the placebo moxibustion group, the same acupuncture points as the treatment group are used. The same type of moxa stick is ignited but kept 8&#x02013;10&#x000a0;cm above the acupuncture point. The temperature of the acupuncture point is similarly monitored but maintained at 37&#x02009;&#x000b1;&#x02009;1&#x000a0;&#x000b0;C so that the subjects do not to feel warm at the points. The treatment cycle and follow-up time are the same as the treatment group.</p></sec></sec><sec id="Sec12"><title>Outcome measurements</title><sec id="Sec13"><title>Primary outcome</title><sec id="FPar1"><title>Adequate relief</title><p>Adequate relief (AR) is used to evaluate the degree of alleviation of IBS symptoms, with relief of abdominal pain or abdominal discomfort as the criterion. During the treatment and follow-up, the patients evaluate themselves once every week. The primary endpoint is set at the end of the treatment (week 6), and the statistics are also performed during follow-ups (weeks 12 and 18) for efficacy duration assessment. &#x0201c;Yes&#x0201d; is defined as positive symptom improvements in more than 3&#x000a0;weeks during the 6-week period; &#x0201c;no&#x0201d; is defined as positive symptom improvements in less than 3&#x000a0;weeks [<xref ref-type="bibr" rid="CR18">18</xref>]. The indicator has been applied in several studies [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] and was found to have significant correlations with intestinal function and QOL [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec></sec><sec id="Sec14"><title>Secondary outcomes</title><sec id="FPar2"><title>IBS Symptom severity score</title><p>IBS symptom severity score (SSS) [<xref ref-type="bibr" rid="CR22">22</xref>] is used to evaluate the degree of severity of IBS-D in the patients. A total score of 500 is calculated from abdominal pain degree, abdominal pain frequency, abdominal distension degree, defecation satisfaction, and influence on life. If the score is lower than 75, the patient is considered to be in remission. The mild, moderate, and severe boundary values are 75&#x02013;175, 175&#x02013;300, and above 300, respectively. The effectiveness, reliability, and sensitivity of IBS SSS to treatment are verified.</p></sec><sec id="FPar3"><title>Bristol stool form scale</title><p>Grading standard in the Bristol stool form scale (BSS) [<xref ref-type="bibr" rid="CR23">23</xref>] is employed to record stool characteristics of the patients with IBS-D in this study. The scale is a visual descriptive figure reflecting gastrointestinal transit time. The total score of the scale ranges from 1 to 7 according to the 1&#x02013;7 types (from constipation to diarrhea) of stool characteristics.</p></sec><sec id="FPar4"><title>Irritable bowel syndrome quality-of-life questionnaire</title><p>Irritable bowel syndrome quality-of-life questionnaire (IBS-QOL) is a specialized scale developed by Patrick et al. [<xref ref-type="bibr" rid="CR24">24</xref>] for patients with IBS. It is composed of 34 items of self-assessment ranging from dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, to sexual relationships, to assess QOL. The patients&#x02019; QOL is measured by a 5-point linear scale, and each question has a 5-point Likert scale (score 1&#x02013;5). The total score of the scale ranges from 34 to 170. The scale achieves good measurement validity.</p></sec><sec id="FPar5"><title>Hospital anxiety and depression scale</title><p>Hospital anxiety and depression scale (HADS) is used to assess the level of anxiety and depression in patients with IBS-D [<xref ref-type="bibr" rid="CR25">25</xref>]. It comprises 14 questions, with seven questions each on anxiety and depression. Each question has a 4-point Likert scale (score 0&#x02013;3). The total score of the scale ranges from 0 to 42. A score greater than 8 in each subscale indicates anxiety/depression.</p><p>IBS-SSS and BSS are completed before treatment (week 0), at the end of treatment (week 6), and during follow-ups (weeks 12 and 18). IBS-QOL and HADS are completed before treatment (week 0) and at the end of treatment (week 6). All the assessments are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Trial flowchart</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Items</th><th>Before enrolment (weeks) &#x02013;4 to 0</th><th>Intervention period (weeks) 1&#x02013;6</th><th>End of 6-week treatment (weeks)</th><th>Follow-up (weeks) 7&#x02013;12</th><th>End of 12-week follow-up (weeks)</th><th>Follow-up (weeks) 13&#x02013;18</th><th>End of 18-week follow-up (weeks)</th></tr></thead><tbody><tr><td colspan="2">Recruitment</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="2">Enrolment</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="2">Inclusion criteria</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="2">Exclusion criteria</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="2">Informed consent</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="2">Basic characteristic variables</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/></tr><tr><td colspan="2">Randomization and allocation concealment</td><td>&#x000d7;</td><td/><td/><td/><td/><td/><td/></tr><tr><td>Primary outcomes</td><td>AR</td><td/><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td><td>&#x000d7;</td></tr><tr><td rowspan="4">Secondary outcomes</td><td>SSS</td><td>&#x000d7;</td><td/><td>&#x000d7;</td><td/><td>&#x000d7;</td><td/><td>&#x000d7;</td></tr><tr><td>BSS</td><td>&#x000d7;</td><td/><td>&#x000d7;</td><td/><td>&#x000d7;</td><td/><td>&#x000d7;</td></tr><tr><td>IBS-QOL</td><td>&#x000d7;</td><td/><td>&#x000d7;</td><td/><td/><td/><td/></tr><tr><td>HADS</td><td>&#x000d7;</td><td/><td>&#x000d7;</td><td/><td/><td/><td/></tr><tr><td colspan="2">Safety outcome</td><td/><td/><td>&#x000d7;</td><td/><td>&#x000d7;</td><td/><td>&#x000d7;</td></tr><tr><td colspan="2">Statistical analysis</td><td/><td/><td>&#x000d7;</td><td/><td>&#x000d7;</td><td/><td>&#x000d7;</td></tr></tbody></table></table-wrap>
</p></sec></sec></sec><sec id="Sec15"><title>Safety outcome</title><p>In this study, possible adverse events during moxibustion include skin burns, blisters, pruritus, dizziness, and respiratory symptoms. The researchers record and deal with all the adverse events (no matter whether it is relevant with moxibustion). When necessary, the researchers can decide whether the trial is terminated.</p></sec><sec id="Sec16"><title>Quality control</title><p>All the researchers are practicing doctors certified by the Ministry of Health of the People&#x02019;s Republic of China. They must have more than 5&#x000a0;years of clinical experience and be qualified as attending physicians. All the researchers are trained to improve consistency among subjects. The outcomes are assessed for all the subjects. The outcome measurement data are preserved in the original case report form (CRF), and supervised and checked by a qualified clinical research coordinator. The original data are recorded into the electronic medical records using a double data entry method by trained researchers, and the electronic data are consistent with the original data. To improve compliance of the subjects, each subject who completes the trial is provided a cash reward.</p></sec><sec id="Sec17"><title>Data monitoring</title><p>This study has set up an independent clinical trial data monitoring committee (DMC), which comprises a medical expert and two clinical research experts. The DMC verifies whether the trial follows the study design and the standard guidelines, checks research progress and the accuracy and authenticity of the CRF, and checks whether the reasons for discontinuation of subjects and adverse events have been recorded in detail in the CRF. In the case of any serious adverse events, the DMC discusses with the institutional review board and the principal investigator, and the principal investigator makes a final decision on the continuation or termination of the trial. In addition, the institutional review board also makes recommendation to the principal investigator on stopping the trial if a serious adverse event occurs.</p></sec><sec id="Sec18"><title>Statistical analysis</title><p>The statisticians are responsible for coordinating research efforts, making a statistical analysis plan, and building a research database. Both intention-to-treat and per-protocol analyses are performed. The last-observation-carried-forward method is used for missing data in the intention-to-treat analysis. SPSS16.0 software is used to analyze the data. Measurement data are first tested using the normality test. Data conforming to the normal distributions are expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation, while data not conforming to the normal distributions are expressed as M (P25&#x02013;P75). A paired <italic>t</italic> test or nonparametric test is used to perform intragroup comparison, and a two-sample <italic>t</italic> test or nonparametric test is used to perform comparison among groups. Enumeration data is expressed as a case (ratio) and analyzed using the <italic>&#x003c7;</italic>
<sup>2</sup> test. Statistic significance is defined as <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec19"><title>Discussion</title><p>The present study assesses the efficacy and safety of mild-warm moxibustion treatment in patients with IBS-D through a multi-center, randomized, single-blind and placebo-controlled trial.</p><p>To confirm the efficacy of mild-warm moxibustion, placebo moxibustion is used as control which is included to eliminate potential placebo effect of moxibustion treatment. Methods for designing a placebo control group for mild-warm moxibustion were limited in the past. One study [<xref ref-type="bibr" rid="CR26">26</xref>] used a 0.5&#x000a0;cm diameter moxa cone as a placebo in a blind trial. However, this method is impractical in our research design because the moxa stick used for warm moxibustion has to be longer than 1.5&#x000a0;cm which is also the most widely used specification in clinical practice.</p><p>At least two conditions should be satisfied in the design of placebo-controlled moxibustion: one is that the placebo model has no specific therapeutic function, the other is that subjects cannot perceive the difference between the placebo moxibustion and the real one. It has been proved that thermal stimulation is an important factor that influences the treatment efficacy, as the heat must reach a certain level to exert the effect [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. In this study, we use a moxa stick of 3&#x000a0;cm diameter to achieve better efficacy through stimulating the acupuncture points for more heat. Due to the unique nature of moxibustion treatment, if the heat stimulus was fully shielding, the participants will not be well blinded. Therefore, we try to reduce the heat stimulation of moxibustion to a minimum, while blind to the participants. The distance of the moxa stick to the acupuncture points in the placebo control group is set to 8&#x02013;10&#x000a0;cm, and the temperature of the acupuncture point is maintained at 37&#x02009;&#x000b1;&#x02009;1&#x000a0;&#x000b0;C. At this temperature, the subjects will feel &#x0201c;lukewarm&#x0201d;, because the temperature of human skin is between 30 and 36&#x000a0;&#x000b0;C with the average temperature at 33.5&#x02009;&#x000b1;&#x02009;0.5&#x000a0;&#x000b0;C. In contrast, the distance of the moxa stick to the acupuncture points in the treatment group is set to 3&#x02013;5&#x000a0;cm, so that the subjects feel warm without any burning pain. The temperature of the acupuncture point is maintained at 43&#x02009;&#x000b1;&#x02009;1&#x000a0;&#x000b0;C, which is shown to contribute to the efficacy of moxibustion treatment [<xref ref-type="bibr" rid="CR29">29</xref>]. It is important to mention that the subjects will be enrolled with no history of acupuncture and moxibustion treatment, and are not aware of the manipulation of moxibustion. Furthermore, they will be treated in individual isolated rooms, which prevent them from communicating with each other. Hence, the environment is conducive to perform the trial.</p><p>A limitation of the trial is that the study cannot double-blind the physicians and subjects. Thus, potential subjective factors in the clinician&#x02019;s approach to the task and possible awareness of the subjects about the treatment they receive may lead to bias of the study.</p><p>The present protocol may demonstrate moxibustion as a safe and effective treatment for patients with IBS-D. If the goals of the study are achieved, we will provide new evidence that moxibustion may be an effective therapy for treating IBS-D. The low-cost, easy-applicable treatment will reduce the financial burden for the patients and healthcare system, relieve the medical burden of hospitals and save medical resources.</p><sec id="Sec20"><title>Trial status</title><p>The trial is currently in the recruitment phase. Participant recruitment started in April 2015, and is expected to end in December 2017.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AR</term><def><p>Adequate relief</p></def></def-item><def-item><term>BSS</term><def><p>Bristol stool form scale</p></def></def-item><def-item><term>CRF</term><def><p>Case report form</p></def></def-item><def-item><term>DMC</term><def><p>Data monitoring committee</p></def></def-item><def-item><term>HADS</term><def><p>Hospital anxiety and depression scale</p></def></def-item><def-item><term>IBS</term><def><p>Irritable bowel syndrome</p></def></def-item><def-item><term>IBS-D</term><def><p>Diarrhea-predominant irritable bowel syndrome</p></def></def-item><def-item><term>IBS-QOL</term><def><p>Irritable bowel syndrome quality-of-life</p></def></def-item><def-item><term>IBS-SSS</term><def><p>Irritable bowel syndrome symptom severity score</p></def></def-item><def-item><term>TCM</term><def><p>Traditional Chinese medicine</p></def></def-item></def-list></glossary><ack><p>The authors would like to thank Dr Zhe Ma and Yi Wang for helping to recruit patients and Dr Lili Ma for screening of eligible subjects in this trial. The authors would also like to express appreciation to Dr Xiaoming Jin for revising the manuscript.</p><sec id="FPar6"><title>Funding</title><p>This study has been supported by the National Key Basic Research Program of China (973 program) (2015CB554501); the National Natural Science Foundation of China (81503656); the Shanghai Sailing Program (15YF1411200); and the Shanghai Municipal Health Bureau (20154Y0138).</p></sec><sec id="FPar7"><title>Availability of data and material</title><p>The datasets supporting the conclusions of this article are included within the article.</p></sec><sec id="FPar8"><title>Authors&#x02019; contributions</title><p>CHB, JZZ, and JML participated in the design of the study and drafted the manuscript. HRL and LYW participated in the statistical design and helped in the design of the study. SYW and YS helped to draft the manuscript. CHB, JZZ, JML, JL, ZHH, YZD and XQZ recruited participants from clinics and communities. HGW conceived the study and was the general supervisor for this research. All authors have read and approved the final manuscript.</p></sec><sec id="FPar9"><title>Competing interests</title><p>The authors declare that they have no competing interest.</p></sec><sec id="FPar10"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar11"><title>Ethics approval and consent to participate</title><p>The study has been approved by the Institutional Review Board of the Yueyang Hospital of Integrated Chinese and Western Medicine, affiliated with the Shanghai University of Traditional Chinese Medicine. The present research is registered in the Clinical Trials database (NCT02421627, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>). The study has strictly met the requirements of the Declaration of Helsinki, and all the subjects will sign informed consent.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keszthelyi</surname><given-names>D</given-names></name><name><surname>Troost</surname><given-names>FJ</given-names></name><name><surname>Masclee</surname><given-names>AA</given-names></name></person-group><article-title>Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Methods to assess visceral hypersensitivity in irritable bowel syndrome</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2012</year><volume>303</volume><fpage>G141</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00060.2012</pub-id><pub-id pub-id-type="pmid">22595988</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Kurlander</surname><given-names>J</given-names></name><name><surname>Eswaran</surname><given-names>S</given-names></name></person-group><article-title>Irritable bowel syndrome: a clinical review</article-title><source>JAMA</source><year>2015</year><volume>313</volume><fpage>949</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.0954</pub-id><pub-id pub-id-type="pmid">25734736</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lovell</surname><given-names>RM</given-names></name><name><surname>Ford</surname><given-names>AC</given-names></name></person-group><article-title>Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis</article-title><source>Clin Gastroenterol Hepatol</source><year>2012</year><volume>10</volume><issue>7</issue><fpage>712</fpage><lpage>721.e4</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2012.02.029</pub-id><pub-id pub-id-type="pmid">22426087</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soubieres</surname><given-names>A</given-names></name><name><surname>Pimentel</surname><given-names>M</given-names></name><name><surname>Purdy</surname><given-names>C</given-names></name><name><surname>Magar</surname><given-names>R</given-names></name></person-group><article-title>Inclusion of a novel IBS blood panel for diagnosing diarrhea predominant irritable bowel syndrome (IBS-D): a UK perspective</article-title><source>Value Health</source><year>2015</year><volume>18</volume><fpage>A350</fpage><pub-id pub-id-type="doi">10.1016/j.jval.2015.09.634</pub-id><pub-id pub-id-type="pmid">26531982</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilleri</surname><given-names>M</given-names></name></person-group><article-title>Management of the irritable bowel syndrome</article-title><source>Gastroenterology</source><year>2001</year><volume>120</volume><fpage>652</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1053/gast.2001.21908</pub-id><pub-id pub-id-type="pmid">11179242</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandler</surname><given-names>RS</given-names></name><name><surname>Everhart</surname><given-names>JE</given-names></name><name><surname>Donowitz</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>E</given-names></name><name><surname>Cronin</surname><given-names>K</given-names></name><name><surname>Goodman</surname><given-names>C</given-names></name><etal/></person-group><article-title>The burden of selected digestive diseases in the United States</article-title><source>Gastroenterology</source><year>2002</year><volume>122</volume><fpage>1500</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1053/gast.2002.32978</pub-id><pub-id pub-id-type="pmid">11984534</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basilisco</surname><given-names>G</given-names></name></person-group><article-title>Pathogenesis of irritable bowel syndrome: current understanding</article-title><source>Recenti Prog Med</source><year>2007</year><volume>98</volume><fpage>543</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18044402</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiller</surname><given-names>R</given-names></name><name><surname>Aziz</surname><given-names>Q</given-names></name><name><surname>Creed</surname><given-names>F</given-names></name><name><surname>Emmanuel</surname><given-names>A</given-names></name><name><surname>Houghton</surname><given-names>L</given-names></name><name><surname>Houghton</surname><given-names>L</given-names></name><etal/></person-group><article-title>Guidelines on the irritable bowel syndrome: mechanisms and practical management</article-title><source>Gut</source><year>2007</year><volume>56</volume><fpage>1770</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1136/gut.2007.119446</pub-id><pub-id pub-id-type="pmid">17488783</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Li</surname><given-names>SC</given-names></name></person-group><article-title>Treatment of irritable bowel syndrome in China: A review</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><fpage>2315</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i8.2315</pub-id><pub-id pub-id-type="pmid">25741137</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundmann</surname><given-names>O</given-names></name><name><surname>Yoon</surname><given-names>SL</given-names></name></person-group><article-title>Complementary and alternative medicines in irritable bowel syndrome: an integrative view</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>346</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i2.346</pub-id><pub-id pub-id-type="pmid">24574705</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magge</surname><given-names>SS</given-names></name><name><surname>Wolf</surname><given-names>JL</given-names></name></person-group><article-title>Complementary and alternative medicine and mind-body therapies for treatment of irritable bowel syndrome in women</article-title><source>Womens Health (Lond Engl)</source><year>2013</year><volume>9</volume><fpage>557</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.2217/whe.13.57</pub-id><pub-id pub-id-type="pmid">24161308</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name></person-group><article-title>Moxibustion in the management of irritable bowel syndrome: systematic review and meta-analysis</article-title><source>BMC Complement Altern Med</source><year>2013</year><volume>13</volume><fpage>247</fpage><pub-id pub-id-type="doi">10.1186/1472-6882-13-247</pub-id><pub-id pub-id-type="pmid">24088418</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>YX</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>CZ</given-names></name><name><surname>Wang</surname><given-names>LP</given-names></name><name><surname>Gou</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>ZL</given-names></name><etal/></person-group><article-title>Randomized clinical trial: the clinical effects of herb-partitioned moxibustion in patients with diarrhoea-predominant irritable bowel syndrome</article-title><source>Evid Based Complement Alternat Med</source><year>2013</year><volume>2013</volume><fpage>605460</fpage><pub-id pub-id-type="pmid">24454500</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longstreth</surname><given-names>GF</given-names></name><name><surname>Thampson</surname><given-names>WG</given-names></name><name><surname>Chey</surname><given-names>WD</given-names></name><name><surname>Houghton</surname><given-names>LA</given-names></name><name><surname>Mearin</surname><given-names>F</given-names></name><name><surname>Spiller</surname><given-names>RC</given-names></name></person-group><article-title>Functional bowel disorders</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>1480</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2005.11.061</pub-id><pub-id pub-id-type="pmid">16678561</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>HR</given-names></name><name><surname>Ma</surname><given-names>XP</given-names></name><name><surname>Wu</surname><given-names>LY</given-names></name><name><surname>Wang</surname><given-names>XM</given-names></name><etal/></person-group><article-title>Clinical and experimental studies on moxibustion for treatment of irritable bowel syndrome</article-title><source>Chin J Tradit Chin Med Pharm</source><year>2010</year><volume>12</volume><fpage>2224</fpage><lpage>7</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaptchuk</surname><given-names>TJ</given-names></name><name><surname>Delley</surname><given-names>JM</given-names></name><name><surname>Conboy</surname><given-names>LA</given-names></name><name><surname>Davis</surname><given-names>RB</given-names></name><name><surname>Kerr</surname><given-names>CE</given-names></name><name><surname>Jacobson</surname><given-names>EE</given-names></name><etal/></person-group><article-title>Components of placebo effect: randomized controlled trial in patients with irritable bowel syndrome</article-title><source>BMJ</source><year>2008</year><volume>336</volume><fpage>999</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1136/bmj.39524.439618.25</pub-id><pub-id pub-id-type="pmid">18390493</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>General Administration of Quality Supervision, Inspection and Quarantine of the People&#x02019;s Republic of China, Standardization Administration of the People&#x02019;s Republic of China</collab></person-group><source>Nomenclature and location of acupuncture points (GB/T 12346-2006)</source><year>2006</year><publisher-loc>Beijing</publisher-loc><publisher-name>China Standards Publishers</publisher-name><fpage>11</fpage><lpage>2</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilleri</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>EA</given-names></name><name><surname>Drossmana</surname><given-names>A</given-names></name><name><surname>Heath</surname><given-names>A</given-names></name><name><surname>Dukes</surname><given-names>GE</given-names></name><name><surname>McSorley</surname><given-names>D</given-names></name><etal/></person-group><article-title>Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist</article-title><source>Aliment Pharmacol Ther</source><year>1999</year><volume>13</volume><fpage>1149</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.1999.00610.x</pub-id><pub-id pub-id-type="pmid">10468696</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lembo</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>HC</given-names></name><name><surname>Farraye</surname><given-names>FA</given-names></name></person-group><article-title>Alosetron in irritable bowel syndrome: strategis for its use in a common gastrointestinal disorder</article-title><source>Drugs</source><year>2003</year><volume>63</volume><fpage>1895</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.2165/00003495-200363180-00002</pub-id><pub-id pub-id-type="pmid">12930162</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyhlin</surname><given-names>H</given-names></name><name><surname>Bang</surname><given-names>C</given-names></name><name><surname>Elsborg</surname><given-names>L</given-names></name><name><surname>Silvennoinen</surname><given-names>J</given-names></name><name><surname>Holme</surname><given-names>I</given-names></name><name><surname>R&#x000fc;egg</surname><given-names>P</given-names></name><etal/></person-group><article-title>A double-blind, Placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome</article-title><source>Scand J Gastroenterol</source><year>2004</year><volume>39</volume><fpage>119</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1080/00365520310006748</pub-id><pub-id pub-id-type="pmid">15000272</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangel</surname><given-names>AW</given-names></name><name><surname>Hahn</surname><given-names>BA</given-names></name><name><surname>Heath</surname><given-names>AT</given-names></name><name><surname>Northcutt</surname><given-names>AR</given-names></name><name><surname>Kong</surname><given-names>S</given-names></name><name><surname>Dukes</surname><given-names>GE</given-names></name><etal/></person-group><article-title>Adequate relief as an endpoint in clinical trials in irritable bowel syndrome</article-title><source>J Int Med Res</source><year>1998</year><volume>26</volume><fpage>76</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">9602985</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>CY</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Whorwell</surname><given-names>PJ</given-names></name></person-group><article-title>The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress</article-title><source>Aliment Pharmacol Ther</source><year>1997</year><volume>11</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.1997.142318000.x</pub-id><pub-id pub-id-type="pmid">9146781</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>SJ</given-names></name><name><surname>Heaton</surname><given-names>KW</given-names></name></person-group><article-title>Stool form scale as a useful guide to intestinal transit time</article-title><source>Scand J Gastroenterol</source><year>1997</year><volume>32</volume><fpage>920</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.3109/00365529709011203</pub-id><pub-id pub-id-type="pmid">9299672</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>DL</given-names></name><name><surname>Drossman</surname><given-names>DA</given-names></name><name><surname>Frederick</surname><given-names>IO</given-names></name><name><surname>Dicesare</surname><given-names>J</given-names></name><name><surname>Puder</surname><given-names>KL</given-names></name></person-group><article-title>Quality of life in persons with irritable bowel syndrome: development and validation of a new measure</article-title><source>Dig Dis Sci</source><year>1998</year><volume>43</volume><fpage>400</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1023/A:1018831127942</pub-id><pub-id pub-id-type="pmid">9512138</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>AS</given-names></name><name><surname>Snaith</surname><given-names>RP</given-names></name></person-group><article-title>The hospital anxiety and depression scale</article-title><source>Acta Psychiatr Scand</source><year>1983</year><volume>67</volume><fpage>361</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0447.1983.tb09716.x</pub-id><pub-id pub-id-type="pmid">6880820</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Lao</surname><given-names>L</given-names></name></person-group><article-title>A novel sham moxibustion device: a randomized, placebo-controlled trial</article-title><source>Complement Ther Med</source><year>2006</year><volume>14</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.ctim.2005.06.003</pub-id><pub-id pub-id-type="pmid">16473754</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pach</surname><given-names>D</given-names></name><name><surname>Brinkhaus</surname><given-names>B</given-names></name><name><surname>Willich</surname><given-names>SN</given-names></name></person-group><article-title>Moxa sticks: thermal properties and possible implications for clinical trials</article-title><source>Complement Ther Med</source><year>2009</year><volume>17</volume><fpage>243</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.ctim.2009.01.002</pub-id><pub-id pub-id-type="pmid">19632553</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>SH</given-names></name></person-group><article-title>Thermal properties of direct and indirect moxibustion</article-title><source>J Acupunct Meridian Stud</source><year>2009</year><volume>2</volume><fpage>273</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S2005-2901(09)60068-6</pub-id><pub-id pub-id-type="pmid">20633502</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Yi</surname><given-names>SH</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Yin</surname><given-names>CS</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Heat stimulation on the skin for medical treatment: can it be controlled?</article-title><source>J Altern Complement Med</source><year>2011</year><volume>17</volume><fpage>497</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1089/acm.2010.0072</pub-id><pub-id pub-id-type="pmid">21649516</pub-id></element-citation></ref></ref-list></back></article>